NASDAQ:CFMS

Conformis Competitors

$0.83
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.80
Now: $0.83
$0.85
50-Day Range
$0.83
MA: $1.01
$1.24
52-Week Range
$0.60
Now: $0.83
$1.49
Volume1.82 million shs
Average Volume5.59 million shs
Market Capitalization$152.33 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63

Competitors

Conformis (NASDAQ:CFMS) Vs. SIEN, IVC, SMTI, LAKE, SRGA, and SRGA

Should you be buying CFMS stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Conformis, including Sientra (SIEN), Invacare (IVC), Sanara MedTech (SMTI), Lakeland Industries (LAKE), Surgalign (SRGA), and Surgalign (SRGA).

Conformis (NASDAQ:CFMS) and Sientra (NASDAQ:SIEN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Insider and Institutional Ownership

30.2% of Conformis shares are held by institutional investors. Comparatively, 71.0% of Sientra shares are held by institutional investors. 3.2% of Conformis shares are held by insiders. Comparatively, 2.8% of Sientra shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Conformis and Sientra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Conformis-32.11%-174.01%-32.59%
Sientra-123.88%-174.05%-38.97%

Risk and Volatility

Conformis has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Sientra has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Conformis and Sientra, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Conformis01302.75
Sientra00403.00

Conformis currently has a consensus target price of $2.3333, indicating a potential upside of 179.68%. Sientra has a consensus target price of $10.00, indicating a potential upside of 43.27%. Given Conformis' higher possible upside, equities analysts plainly believe Conformis is more favorable than Sientra.

Valuation and Earnings

This table compares Conformis and Sientra's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conformis$77.43 million1.97$-28,480,000.00($0.44)-1.90
Sientra$83.70 million4.78$-106,820,000.00($2.29)-3.05

Conformis has higher earnings, but lower revenue than Sientra. Sientra is trading at a lower price-to-earnings ratio than Conformis, indicating that it is currently the more affordable of the two stocks.

Summary

Conformis beats Sientra on 8 of the 14 factors compared between the two stocks.

Invacare (NYSE:IVC) and Conformis (NASDAQ:CFMS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Risk & Volatility

Invacare has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Conformis has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Insider and Institutional Ownership

96.7% of Invacare shares are owned by institutional investors. Comparatively, 30.2% of Conformis shares are owned by institutional investors. 3.2% of Invacare shares are owned by insiders. Comparatively, 3.2% of Conformis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Invacare and Conformis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invacare-4.87%-8.76%-3.07%
Conformis-32.11%-174.01%-32.59%

Earnings and Valuation

This table compares Invacare and Conformis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invacare$927.96 million0.31$-53,330,000.00($1.06)-7.90
Conformis$77.43 million1.97$-28,480,000.00($0.44)-1.90

Conformis has lower revenue, but higher earnings than Invacare. Invacare is trading at a lower price-to-earnings ratio than Conformis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Invacare and Conformis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invacare00103.00
Conformis01302.75

Invacare currently has a consensus price target of $17.00, suggesting a potential upside of 103.11%. Conformis has a consensus price target of $2.3333, suggesting a potential upside of 179.68%. Given Conformis' higher possible upside, analysts plainly believe Conformis is more favorable than Invacare.

Sanara MedTech (NASDAQ:SMTI) and Conformis (NASDAQ:CFMS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Sanara MedTech and Conformis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sanara MedTech0000N/A
Conformis01302.75

Conformis has a consensus target price of $2.3333, suggesting a potential upside of 179.68%. Given Conformis' higher probable upside, analysts clearly believe Conformis is more favorable than Sanara MedTech.

Profitability

This table compares Sanara MedTech and Conformis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sanara MedTech-39.58%-175.36%-55.40%
Conformis-32.11%-174.01%-32.59%

Volatility & Risk

Sanara MedTech has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, Conformis has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.

Valuation and Earnings

This table compares Sanara MedTech and Conformis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanara MedTech$11.77 million19.29$-2,810,000.00N/AN/A
Conformis$77.43 million1.97$-28,480,000.00($0.44)-1.90

Sanara MedTech has higher earnings, but lower revenue than Conformis.

Insider & Institutional Ownership

30.2% of Conformis shares are held by institutional investors. 78.4% of Sanara MedTech shares are held by insiders. Comparatively, 3.2% of Conformis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Conformis beats Sanara MedTech on 8 of the 12 factors compared between the two stocks.

Lakeland Industries (NASDAQ:LAKE) and Conformis (NASDAQ:CFMS) are both small-cap industrial products companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Profitability

This table compares Lakeland Industries and Conformis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lakeland Industries18.93%28.75%24.67%
Conformis-32.11%-174.01%-32.59%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Lakeland Industries and Conformis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lakeland Industries00203.00
Conformis01302.75

Lakeland Industries presently has a consensus target price of $31.3333, suggesting a potential upside of 11.15%. Conformis has a consensus target price of $2.3333, suggesting a potential upside of 179.68%. Given Conformis' higher possible upside, analysts clearly believe Conformis is more favorable than Lakeland Industries.

Volatility and Risk

Lakeland Industries has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, Conformis has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Institutional & Insider Ownership

70.8% of Lakeland Industries shares are held by institutional investors. Comparatively, 30.2% of Conformis shares are held by institutional investors. 4.9% of Lakeland Industries shares are held by insiders. Comparatively, 3.2% of Conformis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Lakeland Industries and Conformis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakeland Industries$107.81 million2.10$3.28 million$0.4562.64
Conformis$77.43 million1.97$-28,480,000.00($0.44)-1.90

Lakeland Industries has higher revenue and earnings than Conformis. Conformis is trading at a lower price-to-earnings ratio than Lakeland Industries, indicating that it is currently the more affordable of the two stocks.

Summary

Lakeland Industries beats Conformis on 11 of the 14 factors compared between the two stocks.

Surgalign (NASDAQ:SRGA) and Conformis (NASDAQ:CFMS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Analyst Recommendations

This is a summary of recent ratings for Surgalign and Conformis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Surgalign00403.00
Conformis01302.75

Surgalign presently has a consensus target price of $4.3333, suggesting a potential upside of 126.88%. Conformis has a consensus target price of $2.3333, suggesting a potential upside of 179.68%. Given Conformis' higher probable upside, analysts clearly believe Conformis is more favorable than Surgalign.

Risk and Volatility

Surgalign has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Conformis has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.

Profitability

This table compares Surgalign and Conformis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Surgalign-56.07%-101.34%-18.44%
Conformis-32.11%-174.01%-32.59%

Insider and Institutional Ownership

53.5% of Surgalign shares are held by institutional investors. Comparatively, 30.2% of Conformis shares are held by institutional investors. 3.7% of Surgalign shares are held by insiders. Comparatively, 3.2% of Conformis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Surgalign and Conformis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgalign$308.38 million0.68$-211,640,000.00($0.16)-11.94
Conformis$77.43 million1.97$-28,480,000.00($0.44)-1.90

Conformis has lower revenue, but higher earnings than Surgalign. Surgalign is trading at a lower price-to-earnings ratio than Conformis, indicating that it is currently the more affordable of the two stocks.

Summary

Surgalign beats Conformis on 10 of the 14 factors compared between the two stocks.

Surgalign (NASDAQ:SRGA) and Conformis (NASDAQ:CFMS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares Surgalign and Conformis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgalign$308.38 million0.68$-211,640,000.00($0.16)-11.94
Conformis$77.43 million1.97$-28,480,000.00($0.44)-1.90

Conformis has lower revenue, but higher earnings than Surgalign. Surgalign is trading at a lower price-to-earnings ratio than Conformis, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Surgalign has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Conformis has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.

Institutional & Insider Ownership

53.5% of Surgalign shares are held by institutional investors. Comparatively, 30.2% of Conformis shares are held by institutional investors. 3.7% of Surgalign shares are held by insiders. Comparatively, 3.2% of Conformis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Surgalign and Conformis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Surgalign-56.07%-101.34%-18.44%
Conformis-32.11%-174.01%-32.59%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Surgalign and Conformis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Surgalign00403.00
Conformis01302.75

Surgalign presently has a consensus price target of $4.3333, indicating a potential upside of 126.88%. Conformis has a consensus price target of $2.3333, indicating a potential upside of 179.68%. Given Conformis' higher probable upside, analysts clearly believe Conformis is more favorable than Surgalign.

Summary

Surgalign beats Conformis on 10 of the 14 factors compared between the two stocks.


Conformis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sientra logo
SIEN
Sientra
1.6$6.98flat$399.77 million$83.70 million-3.92Increase in Short Interest
Invacare logo
IVC
Invacare
1.6$8.37flat$288.13 million$927.96 million-6.80Analyst Downgrade
SMTI
Sanara MedTech
0.8$29.80flat$226.99 million$11.77 million-23.10Decrease in Short Interest
Lakeland Industries logo
LAKE
Lakeland Industries
1.6$28.19flat$226.08 million$107.81 million8.01Upcoming Earnings
Surgalign logo
SRGA
Surgalign
1.7$1.91flat$210.61 million$308.38 million-1.06Increase in Short Interest
Surgalign logo
SRGA
Surgalign
1.4$1.91flat$210.61 million$308.38 million-1.06Increase in Short Interest
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.4$1.93flat$88.96 million$4.87 million-1.53Decrease in Short Interest
CollPlant Biotechnologies logo
CLGN
CollPlant Biotechnologies
1.1$14.70flat$83.35 million$2.32 million-7.35Analyst Downgrade
Decrease in Short Interest
Predictive Oncology logo
POAI
Predictive Oncology
1.3$1.30flat$63.43 million$1.41 million-0.21
AHPI
Allied Healthcare Products
0.5$4.40flat$17.64 million$31.89 million0.00
NanoVibronix logo
NAOV
NanoVibronix
0.5$0.90flat$12.00 million$530,000.00-1.49Decrease in Short Interest
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]at.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.